Previous Article | Next Article ![]()
Journal of Virology, November 2008, p. 11016-11022, Vol. 82, No. 22
0022-538X/08/$08.00+0 doi:10.1128/JVI.00919-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Ashley Shea,
Chandra Inglis,
Lian Ni Lee, and
Sally R. Sarawar*
Viral Immunology, Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121
Received 2 May 2008/ Accepted 25 August 2008
CD4 T cells are not essential for primary clearance of replicating murine gammaherpesvirus 68 (MHV-68) but are required for effective long-term control. The virus reactivates in the lungs of major histocompatibility complex class II-deficient (CII–/–) mice that lack functional CD4 T cells. CD40 ligand (CD40L) is upregulated on activated CD4 T cells, and it is thought that CD40-CD40L interactions are an important component of CD4 T-cell help. Our previous studies have shown that agonistic antibodies to CD40 can substitute for CD4 T-cell function in the long-term control of MHV-68. In the present study, we sought to identify the CD40-positive cell type mediating this effect. To address this question, we adoptively transferred MHV-68 peptide-pulsed CII–/– dendritic cells (DC) that had been treated with an agonistic antibody to CD40 into MHV-68-infected CII–/– recipients. Viral reactivation was significantly lower in mice injected with anti-CD40-treated DC than in those injected with control DC or in mice that did not receive any DC. However, in similar experiments with B cells, anti-CD40 treatment had no effect. We also investigated the requirement for CD40 expression on T cells by adoptive transfer of T cells from CD40+/+ or CD40–/– mice into T-cell-deficient recipients that were subsequently infected with MHV-68. The results showed that CD40 expression on T cells is not necessary for preventing viral reactivation. Taken together, our data suggest that CD40 engagement on DC, but not on T or B cells, is essential for effective long-term control of MHV-68.
Published ahead of print on 3 September 2008.
Present address: Division of Research Immunology and Bone Marrow Transplantation, CHLA, 4650 Sunset Blvd., Los Angeles, CA 90027.
Present address: Novartis, 500 Technology Square, Cambridge, MA 02139.
Present address: Department of Neuroscience, UCSD, 9500 Gilman Drive, #0624, La Jolla, CA 92093-0624.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»